Eptacog alfa biosimilar (AryoGen Biopharma)

依他凝血素α生物类似药 (AryoGen Biopharma)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEptacog alfa biosimilar (AryoGen Biopharma)
Drug Alias Name重组人凝血因子VIIa生物仿制药 (AryoGen Biopharma)依他凝血素α生物仿制药 (AryoGen Biopharma)
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant coagulation factor
Mechanisms of ActionCoagulation factor IX stimulantsCoagulation factor X stimulantsBlood coagulation pathway activation +[4] 
TargetsCoagulation factor IXCoagulation factor X
Therapy Area/IndicationsThrombastheniaHemophilia BHemophilia A +[4] 
Global Approved IndicationsThrombastheniaHemophilia BHemophilia A +[4] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIran
Original Approved Date2014/01/01
Country/TerritoryTurkeyIran
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAryogen Biopharma
China Registration ClassN/A

Develop Information

Active CompaniesAryogen Biopharma
Inactive CompaniesAryogen Pharmed Co
Active IndicationsThrombastheniaHemophilia BHemophilia A +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeB02BD08
Related LinksN/A